159 related articles for article (PubMed ID: 35228217)
21. Amifampridine tablets for the treatment of Lambert-Eaton myasthenic syndrome.
Mantegazza R
Expert Rev Clin Pharmacol; 2019 Nov; 12(11):1013-1018. PubMed ID: 31639317
[No Abstract] [Full Text] [Related]
22. Lambert-Eaton syndrome, an unrecognized treatable pediatric neuromuscular disorder: three patients and literature review.
Hajjar M; Markowitz J; Darras BT; Kissel JT; Srinivasan J; Jones HR
Pediatr Neurol; 2014 Jan; 50(1):11-7. PubMed ID: 24138947
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of intravenous immunoglobulin for treatment of Lambert-Eaton myasthenic syndrome without anti-presynaptic P/Q-type voltage-gated calcium channel antibodies: a case report.
Okada A; Koike H; Nakamura T; Motomura M; Sobue G
Neuromuscul Disord; 2015 Jan; 25(1):70-2. PubMed ID: 25444432
[TBL] [Abstract][Full Text] [Related]
24. Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients.
Tim RW; Massey JM; Sanders DB
Ann N Y Acad Sci; 1998 May; 841():823-6. PubMed ID: 9668336
[No Abstract] [Full Text] [Related]
25. Lambert-Eaton Myasthenic Syndrome and Dermatomyositis With Anti-TIF1-gamma Autoantibody: A Unique Association of Autoimmune Neuromuscular Conditions Without Malignancy.
Isfort M; Mnatsakanova D; Oddis C; Lacomis D
J Clin Neuromuscul Dis; 2021 Mar; 22(3):164-168. PubMed ID: 33596001
[TBL] [Abstract][Full Text] [Related]
26. [Paraneoplastic Cerebellar Degeneration with Lambert-Eaton Myasthenic Syndrome: A Report of an Effectively Treated Case and Systematic Review of Japanese Cases].
Kitanosono H; Motomura M; Tomita H; Iwanaga H; Iwanaga N; Irioka T; Shiraishi H; Tsujino A
Brain Nerve; 2019 Feb; 71(2):167-174. PubMed ID: 30718446
[TBL] [Abstract][Full Text] [Related]
27. Myopathic EMG findings and type II muscle fiber atrophy in patients with Lambert-Eaton myasthenic syndrome.
Crone C; Christiansen I; Vissing J
Clin Neurophysiol; 2013 Sep; 124(9):1889-92. PubMed ID: 23643575
[TBL] [Abstract][Full Text] [Related]
28. [Lambert-Eaton myasthenic syndrome].
Motomura M; Fukuda T
Brain Nerve; 2011 Jul; 63(7):745-54. PubMed ID: 21747145
[TBL] [Abstract][Full Text] [Related]
29. Neuronal antibody detection and improved lung cancer prediction in Lambert-Eaton myasthenic syndrome.
Maddison P; Gozzard P; Sadalage G; Ambrose PA; Chapman CJ; Murray A; Thomsen S; Berretta A; Lang B
J Neuroimmunol; 2020 Mar; 340():577149. PubMed ID: 31951874
[TBL] [Abstract][Full Text] [Related]
30. Paraneoplastic Lambert-Eaton myasthenic syndrome: a diagnostic challenge.
Viveiros L; Martins SR; Pires SX; Neves J
BMJ Case Rep; 2023 Jan; 16(1):. PubMed ID: 36707096
[TBL] [Abstract][Full Text] [Related]
31. [Diagnosis and Treatment of Lambert-Eaton Myasthenic Syndrome].
Kitanosono H; Yoshimura S; Shiraishi H; Motomura M
Brain Nerve; 2024 Jan; 76(1):33-40. PubMed ID: 38191137
[TBL] [Abstract][Full Text] [Related]
32. Cancer detection after a 9-year course of Lambert-Eaton myasthenic syndrome complicated by anti-Hu associated limbic encephalitis.
Falso S; Spagni G; Iorio R; Evoli A
Neuromuscul Disord; 2023 Sep; 33(9):90-92. PubMed ID: 37507235
[TBL] [Abstract][Full Text] [Related]
33. Long-term observation of incremental response and antibodies to voltage-gated calcium channels in patients with Lambert-Eaton myasthenic syndrome: two case reports.
Schneider I; Kornhuber ME; Hanisch F
J Med Case Rep; 2015 Mar; 9():59. PubMed ID: 25885033
[TBL] [Abstract][Full Text] [Related]
34. Small-cell lung cancer presenting with Lambert-Eaton myasthenic syndrome and respiratory failure.
Jiang JR; Shih JY; Wang HC; Wu RM; Yu CJ; Yang PC
J Formos Med Assoc; 2002 Dec; 101(12):871-4. PubMed ID: 12632823
[TBL] [Abstract][Full Text] [Related]
35. [Lambert-Eaton myasthenic syndrome, an immune pathology of neuromuscular junctions].
Honnorat J
Bull Acad Natl Med; 2014 Feb; 198(2):243-54; discussion 255. PubMed ID: 26263702
[TBL] [Abstract][Full Text] [Related]
36. Two Lambert-Eaton Myasthenic Syndrome Patients with Ameliorated Activities of Daily Living Due to Cholinesterase Inhibitors.
Yamasaki H; Futamura N; Funakawa I; Kohara N; Yoshimura S; Motomura M
Intern Med; 2022 Apr; 61(7):1063-1065. PubMed ID: 34544947
[TBL] [Abstract][Full Text] [Related]
37. Lambert-eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel.
Pellkofer HL; Armbruster L; Krumbholz M; Titulaer MJ; Verschuuren JJ; Schumm F; Voltz R
J Neuroimmunol; 2008 Nov; 204(1-2):136-9. PubMed ID: 18809213
[TBL] [Abstract][Full Text] [Related]
38. [A case of small cell lung carcinoma without apparent primary lesion accompanying Lambert-Eaton myasthenic syndrome].
Kanamori K; Yahata T; Otsuka K; Imanaka M; Yokota I
Nihon Kokyuki Gakkai Zasshi; 2009 Dec; 47(12):1151-5. PubMed ID: 20058696
[TBL] [Abstract][Full Text] [Related]
39. Lambert-eaton myasthenic syndrome in a patient with small-cell lung cancer.
Wang S; Bruzzi J; Rodriguez-Garza VP; Komaki RR
Clin Lung Cancer; 2006 Jan; 7(4):282-4. PubMed ID: 16512985
[TBL] [Abstract][Full Text] [Related]
40. Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management.
Evoli A; Liguori R; Romani A; Mantegazza R; Di Muzio A; Giometto B; Pegoraro E; Rodolico C; Vigliani MC;
Neurol Sci; 2014 Apr; 35(4):515-20. PubMed ID: 24481713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
